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CORRECTIONS
van Eickels M, Patten RD, Aronovitz MJ, Alsheikh-Ali A, Gostyla K, Celestin F, Grohe C, Mendelsohn ME, Karas RH.
17-Beta-Estradiol Increases Cardiac Remodeling and Mortality in Mice With Myocardial Infarction. J Am Coll Cardiol
2003;41:2084 –92. This statement should have appeared in the footnote on the first page of the article: Drs. van Eickels and Patten
contributed equally to this work.
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Cannon CP. Small Molecule Glycoprotein IIb/IIIa Receptor Inhibitors as Upstream Therapy in Acute Coronary Syndromes:
Insights From the TACTICS TIMI-18 Trial. J Am Coll Cardiol 2003;41:43S– 48S. As per the authors, Figure 3 was printed
incorrectly. The correct figure (and legend) are below.
doi:10.1016/S0735-1097(03)00774-5
Figure 3. Benefit of glycoprotein IIb/IIIa inhibition in UA/NSTEMI based on positive or negative troponin levels. CAPTURE  c7E3 AntiPlatelet
Therapy in Unstable REfractory angina to standard treatment; PRISM  Platelet Receptor inhibition for ISchemic Management; TnI  troponin I;
TnT  troponin T. Data from Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation
to serum troponin T levels. N Engl J Med 1999;340:1623–9. Data from Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for
stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757–62. Reprinted with permission
from Elsevier Science.
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